Literature DB >> 27605635

Eligibility For And Enrollment In Medicare Part D Medication Therapy Management Programs Varies By Plan Sponsor.

Bruce Stuart1, Franklin B Hendrick2, Xian Shen3, Mingliang Dai4, Sarah E Tom5, J Samantha Dougherty6, Laura M Miller7.   

Abstract

Medicare Part D prescription drug plans must offer medication therapy management to beneficiaries with multiple chronic conditions and high drug expenditures. However, plan sponsors have considerable latitude in setting eligibility criteria. Newly available data indicate that enrollment rates in medication therapy management among stand-alone prescription drug plans and Medicare Advantage drug plans averaged only 10 percent in 2012. The enrollment variation across plan sponsors-from less than 0.2 percent to more than 57.0 percent-was associated with the restrictiveness of their eligibility criteria. For example, enrollment was 16.4 percent in plans requiring two chronic conditions versus 9.2 percent in plans requiring three, and 12.7 percent in plans requiring the use of any Part D drug versus 4.4 percent in plans requiring the use of drugs in specific classes. This variation represents inequities in access to medication therapy management across plans and results in missed opportunities for interventions that might improve therapeutic outcomes and reduce spending. The new Part D Enhanced Medication Therapy Management model of the Centers for Medicare and Medicaid Services has the potential to significantly increase the impact of medication therapy management by aligning financial incentives with improvements in medication use and encouraging innovation. Project HOPE—The People-to-People Health Foundation, Inc.

Keywords:  Medicare; Medicine/Clinical Issues

Mesh:

Year:  2016        PMID: 27605635     DOI: 10.1377/hlthaff.2016.0258

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  Racial/ethnic disparities in the enrollment of Medication Therapy Management programs among Medicare beneficiaries with Alzheimer's disease and related dementias.

Authors:  Jamie A Browning; Chi Chun Steve Tsang; Rose Zeng; Xiaobei Dong; Joseph Garuccio; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Junling Wang
Journal:  Curr Med Res Opin       Date:  2022-08-09       Impact factor: 2.705

Review 2.  Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.

Authors:  Cori Gray; Catherine E Cooke; Nicole Brandt
Journal:  Am Health Drug Benefits       Date:  2019-09

3.  Effects of the Medicare Part D comprehensive medication review on medication adherence among patients with Alzheimer's disease.

Authors:  Xiaobei Dong; Chi Chun Steve Tsang; Shirong Zhao; Jamie A Browning; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Lisa E Hines; Junling Wang
Journal:  Curr Med Res Opin       Date:  2021-06-24       Impact factor: 2.705

4.  Exploring Racial and Ethnic Disparities in Medication Adherence Among Medicare Comprehensive Medication Review Recipients.

Authors:  Xiaobei Dong; Chi Chun Steve Tsang; Jim Y Wan; Yachen Tina Shih; Marie A Chisholm-Burns; Samuel Dagogo-Jack; William C Cushman; Lisa E Hines; Junling Wang
Journal:  Explor Res Clin Soc Pharm       Date:  2021-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.